Clinical Trials Logo

Epicardial Fat clinical trials

View clinical trials related to Epicardial Fat.

Filter by:
  • None
  • Page 1

NCT ID: NCT04200625 Completed - Epicardial Fat Clinical Trials

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Start date: September 24, 2019
Phase:
Study type: Observational

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

NCT ID: NCT03111693 Recruiting - Obesity Clinical Trials

CT Evaluation of Cardiovascular Risk Markers in Obese Patients

RisqOScan
Start date: November 2014
Phase: N/A
Study type: Observational

Obesity is a chronic metabolic disorder : it leads to coronary heart disease and early atherosclerosis. Coronary artery calcium measured by CT is known as a robust predictor to predict risk for cardiac events in symptomatic and asymptomatic individuals. Furthermore, recent studies show that other CT risk factor exists, independent of calcium scoring, such as epicardial fat, intrathoracic fat and visceral fat. The aim of this prospective study is to evaluate these new cardiovascular risk markers in obese patients, using standard dose CT and low dose CT with adaptative statistical iterative reconstruction.

NCT ID: NCT01344694 Not yet recruiting - Atherosclerosis Clinical Trials

Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

Start date: July 2011
Phase: N/A
Study type: Observational

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.